Last reviewed · How we verify
NCT03098446
The Effect of Sitting and Moderate Exercise on Plasma Triglyceride Elevation After a Meal
NA trial testing Prolonged sitting with exercise in Atherosclerosis in 10 participants. Completed in 11 August 2017.
11 August 2017
Quick facts
| Lead sponsor | University of Texas at Austin |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 10 |
| Start date | 8 April 2017 |
| Primary completion | 11 August 2017 |
| Estimated completion | 11 August 2017 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Prolonged sitting with exercise
- Prolonged sitting without exercise
Conditions studied
- Atherosclerosis — all drugs for Atherosclerosis →
- Metabolic Syndrome — all drugs for Metabolic Syndrome →
Sponsor
University of Texas at Austin
Who can join
Adults 18 to 40, any sex, with Atherosclerosis or Metabolic Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to investigate the effect of 4 days of sitting and moderate exercise on plasma triglyceride elevation after a meal.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03098446
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Prolonged sitting with exercise
Trials testing the same drug.
- NCT03352063 — Prolonged Sitting on Responses to Short-Term Exercise Training · NA · completed
Other recruiting trials for Atherosclerosis
Currently open trials in the same condition.
- NCT07448038 — A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vas · Phase 2 · recruiting
- NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
- NCT06788431 — A Clinical Study of IMC-001 for Injection in Improving Atherosclerotic Plaque Stability in Patients With Acute Coronary · EARLY_PHASE1 · recruiting
- NCT06676046 — Natural History of Uncommon Dyslipidemias, Rare Lipid Disorders and Unusual Atherosclerotic Conditions · recruiting
- NCT06694012 — Osaka Cardiometabolic Epidemiological Study: Ohtori Study Part 2 · recruiting
Other University of Texas at Austin trials
Trials by the same sponsor.
- NCT07319234 — Development of MENU Protocol · NA · not yet recruiting
- NCT07480109 — Increased Dietary Protein Intake During GLP-1 Medication Use (in Middle-aged Women With Overweight/Obesity) · NA · not yet recruiting
- NCT07069413 — Sibwatch: Optimizing Intervention Options for Infants and Toddler Siblings of Autistic Children · NA · not yet recruiting
- NCT07370311 — A Culturally Adapted Decision Aid Intervention to Support Chinese American Dementia Caregivers in Feeding-Related Decisi · NA · not yet recruiting
- NCT07441122 — Enhancing Attention in Elderly Using a Brain-Computer-Interface · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03098446 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Texas at Austin
- Last refreshed: 5 October 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03098446.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing